AI tool uses emergency room narratives to predict PTSD risk

by rss feed | Nov 9, 2026 | News Feeds

An AI tool can analyze patients' narratives about injuries that sent them to the emergency room to predict who will later develop post-traumatic stress disorder (PTSD), a new study found. Read Original...

Alliance highlights clinical trials advancing lung cancer detection and care

by rss feed | Nov 9, 2026 | News Feeds

Lung cancer remains the leading cause of cancer-related deaths in the United States, but advances in early detection and treatment are improving the outlook for patients. Read Original...

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

by rss feed | Nov 9, 2026 | News Feeds

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small...

Better reimbursement programs can improve access to cancer clinical trials

by rss feed | Nov 9, 2026 | News Feeds

New research reveals that participating in cancer clinical trials can cause financial burdens that are shaped by both socioeconomic and logistical factors. Read Original...

Modified zinc finger protein reduces brain plaques in Alzheimer’s mice

by rss feed | Nov 9, 2026 | News Feeds

A KAIST-led research team has found that a protein involved in gene regulation can suppress the harmful aggregation of amyloid-beta, a peptide associated with Alzheimer's disease. Read Original...

Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

by rss feed | Nov 9, 2026 | News Feeds

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced new real-world data showing 68% high-grade recurrence-free survival (HG-RFS) at 12 months in patients with Bacillus Calmette-Guérin...